Suppr超能文献

常用他汀类药物对腹主动脉瘤壁生物学的不同影响。

Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.

机构信息

Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

Eur J Vasc Endovasc Surg. 2010 May;39(5):569-76. doi: 10.1016/j.ejvs.2010.01.030. Epub 2010 Mar 11.

Abstract

BACKGROUND

Pharmaceutical stabilisation of the abdominal aortic aneurysm (AAA) wall can delay surgery and improve outcome. Observational studies indicate statins can be used to reduce AAA growth but mechanistic data are scarce. In this study, our aim was to determine the pleiotropic effects of different statins on AAA wall composition.

METHODS

We included 216 patients undergoing open AAA repair, of which 60 used simvastatin, 52 atorvastatin and 23 pravastatin. The AAA wall histology and protein expression (IL 1beta,2,4,5,6,8,10,12, interferon-gamma (IFNgamma), tumour necrosis factor (TNF)alpha,beta, matrix metalloproteinase (MMP)2 and 9 activities, total MMP8,9 and cathepsin A and B levels) between statin users and non-users were compared as also among the use of different statins.

RESULTS

As far as histological inflammation goes, the AAA walls of statin users did not differ from those not using them. After multivariate adjustment for risk factors, pravastatin use was associated with tendencies of increased MMP8 (p = 0.022), active MMP9 (p = 0.040) and higher cathepsin B (p = 0.056) levels. The AAA walls of simvastatin and atorvastatin users showed no differences in proteases or cytokines in multivariate analyses.

CONCLUSIONS

The use of statins was not associated with a decrease in protease levels or inflammation. The trends of elevated protease levels associated with pravastatin use suggest pleiotropic differences among the various statins, supporting the need for further research to target pharmaceutical AAA treatment.

摘要

背景

药物稳定腹主动脉瘤(AAA)壁可以延迟手术并改善结果。观察性研究表明,他汀类药物可用于减少 AAA 的生长,但机制数据很少。在这项研究中,我们的目的是确定不同他汀类药物对 AAA 壁成分的多效作用。

方法

我们纳入了 216 名接受开放 AAA 修复的患者,其中 60 名使用辛伐他汀,52 名使用阿托伐他汀,23 名使用普伐他汀。比较了他汀类药物使用者和非使用者之间的 AAA 壁组织学和蛋白表达(IL 1beta、2、4、5、6、8、10、12、干扰素-γ(IFNgamma)、肿瘤坏死因子(TNF)alpha、beta、基质金属蛋白酶(MMP)2 和 9 活性、总 MMP8、9 和组织蛋白酶 A 和 B 水平),以及不同他汀类药物的使用情况。

结果

就组织学炎症而言,他汀类药物使用者的 AAA 壁与未使用者无差异。在多变量调整危险因素后,普伐他汀的使用与 MMP8 增加的趋势相关(p = 0.022),活性 MMP9(p = 0.040)和更高的组织蛋白酶 B(p = 0.056)水平。在多变量分析中,辛伐他汀和阿托伐他汀使用者的 AAA 壁在蛋白酶或细胞因子方面没有差异。

结论

他汀类药物的使用与蛋白酶水平的降低或炎症无关。与普伐他汀使用相关的蛋白酶水平升高趋势表明各种他汀类药物之间存在多效性差异,支持需要进一步研究以针对药物治疗 AAA。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验